Literature DB >> 12239944

Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis.

Robert Flisiak1, Paul Maxwell, Danuta Prokopowicz, Peter M Timms, Anatol Panasiuk.   

Abstract

BACKGROUND/AIMS: The role of transforming growth factor-beta 1 (TGF-beta 1) in liver fibrosis is in part related to impairment of extracellular matrix breakdown by stimulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) gene. The aim of the study was to evaluate association between TGF-beta 1 and TIMP-1 in relation to liver injury in chronic viral hepatitis B and C.
METHODOLOGY: Association between plasma TGF-beta 1 and TIMP-1 was evaluated in 28 consecutive patients undergoing liver biopsy for chronic viral hepatitis B and C (CH-B, CH-C) and these tests were correlated with hepatic fibrosis, inflammation and liver function tests. Moreover carboxyterminal cross-linked telopeptide of type 1 procollagen (ICTP) and carboxyterminal propeptide of type 1 collagen (PICP) were also measured for assessment of extracellular matrix breakdown or synthesis, respectively.
RESULTS: Chronic viral hepatitis B and C resulted in a significant increase in plasma TIMP-1 levels but not TGF-beta 1. Among biochemical markers of liver injury, significant correlation with TGF-beta 1 and TIMP-1 was demonstrated in respect to aminotransferase activities in both groups. TIMP-1 showed significant correlation with ICTP levels in both CH-B (r = 0.59) and CH-C (r = 0.62), whereas TGF-beta 1 was correlated with ICTP only in CH-C patients (r = 0.75). PICP did not demonstrate any correlation with either TGF-beta 1 or TIMP-1. Hepatic fibrosis, but not inflammation, correlated significantly with TGF-beta 1 (CH-B: r = 0.73; CH-C: r = 0.79) and TIMP-1 (CH-B: r = 0.66; CH-C: r = 0.71) in both groups and there was a significant correlation between TIMP-1 and TGF-beta 1 in the CH-B group (r = 0.83) and CH-C group (r = 79).
CONCLUSIONS: These results support the role of TIMP-1 in a TGF-beta 1-dependent mechanism for liver fibrosis and suggest their plasma levels can be used as a possible early non-invasive marker of liver fibrosis useful for chronic hepatitis management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239944

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  20 in total

1.  Expression of tissue inhibitor of matrix metalloproteinases-1 during aging in rat liver.

Authors:  Yu-Mei Zhang; Xiang-Mei Chen; Di Wu; Suo-Zhu Shi; Zhong Yin; Rui Ding; Yang Lü
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

2.  Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey.

Authors:  Axel-M Gressner; Chun-Fang Gao; Olav-A Gressner
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

3.  The protective potential of alpha lipoic acid on amiodarone-induced pulmonary fibrosis and hepatic injury in rats.

Authors:  Ghadha Ibrahim Fouad; Mohamed R Mousa
Journal:  Mol Cell Biochem       Date:  2021-05-10       Impact factor: 3.396

4.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

5.  Effects of augmentation of liver regeneration recombinant plasmid on rat hepatic fibrosis.

Authors:  Qing Li; Dian-Wu Liu; Li-Mei Zhang; Bing Zhu; Yu-Tong He; Yong-Hong Xiao
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

6.  Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.

Authors:  Robert Flisiak; Jerzy Jaroszewicz; Tadeusz W Lapinski; Iwona Flisiak; Danuta Prokopowiczi
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

Review 7.  Role of cannabinoids in chronic liver diseases.

Authors:  Anna Parfieniuk; Robert Flisiak
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

Review 8.  Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease.

Authors:  Mark A Feitelson; Helena M G P V Reis; N Lale Tufan; Bill Sun; Jingbo Pan; Zhaorui Lian
Journal:  Cancer Lett       Date:  2009-02-06       Impact factor: 8.679

9.  Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters.

Authors:  Lun-Gen Lu; Min-De Zeng; Mo-Bin Wan; Cheng-Zhong Li; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Ai-Ping Cao; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

10.  Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B.

Authors:  Robert Flisiak; Haza Al-Kadasi; Jerzy Jaroszewicz; Danuta Prokopowicz; Iwona Flisiak
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.